Search Results

You are looking at 1 - 10 of 158 items for :

  • "lenalidomide" x
  • Refine by Access: All x
Clear All
Full access

Ruben Niesvizky and Ashraf Z. Badros

Therapies such as thalidomide, bortezomib, and lenalidomide have provided meaningful benefits in multiple myeloma (MM), such as improved response rates and improved duration of response, but they have been associated with an increased risk of

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

. Induction regimens that incorporate thalidomide, lenalidomide, and/or bortezomib are now standard for newly diagnosed MM in the United States. 8 – 12 Eligible patients may undergo autologous stem cell transplantation (ASCT), which deepens and prolongs the

Full access

Ashraf Z. Badros

randomized clinical trials of bortezomib and lenalidomide are underway ( Table 1 ). 12 Four randomized phase III trials have been completed to establish the role of thalidomide-based maintenance after ASCT ( Table 2 ). 13 – 16 In all 4 studies, improvements

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades, and Kenneth C. Anderson

relapsed multiple myeloma: updated results of the APEX trial [abstract] . Blood 2005 ; 106 : 715a . Abstract 2547 . 20. Weber DM Chen C Niesvizky R . Lenalidomide plus high-dose dexamethasone provides improved survival compared to high

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial . Lancet 2007 ; 370 : 1209 – 1218 . 36 Rajkumar SV Jacobus S Callander N . A randomized phase III trial of lenalidomide plus high

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

IFM 2005/01 trial [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 455s . 31 Rajkumar SV Jacobus S Callander N . A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in

Full access

Ashraf Badros

, bortezomib, and lenalidomide may neutralize the effects of negative prognostic factors. An effective means of risk stratification is required so that patients with poor risk may be offered more aggressive treatment or be entered into clinical trials of novel

Full access

Jean-Luc Harousseau and Philippe Moreau

. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma . Blood 2005 ; 106 : 4050 – 4053 . 27. Siegel DS Desikan KR Mehta J . Age is not a prognostic variable with autotransplants for multiple myeloma

Full access

Maria R. Baer and Ivana Gojo

% to 30% marrow blasts (azacitidine, decitabine) and for other indications (clofarabine, lenalidomide), those denied approval based on testing but that are still under evaluation (tipifarnib), and those still in early testing (sapacitabine). The novel

Full access

Philip L. McCarthy

increased. 1 This improved OS is likely from the use of novel agents that improve PFS, including the immunomodulatory drugs (IMiDs) thalidomide 2 , 3 and lenalidomide, 4 - 7 and the proteasome inhibitor bortezomib. 8 - 13 These drugs, usually as part of